Antithrombin III (ATIII) deficiency offers unique challenges to the anaesthetist in the perioperative setting due to the inherent thrombophilia, the anticoagulant therapies instituted and replacement of the deficient intrinsic natural anticoagulant. A particular challenge is the use of intrathecal anaesthesia, which requires a safe level of coagulation at the time of subarachnoid puncture. We describe the use of intrathecal anaesthesia on two occasions in a patient with ATIII deficiency who received human-derived ATIII concentrate as part of a perioperative anticoagulant regimen. The patient sustained no thrombotic or bleeding events. Our experience suggests that ATIII deficiency does not preclude the use of regional anaesthetic techniques so long as there is timely referral to a multidisciplinary perioperative service for anticoagulant management and that ATIII concentrate is used to ensure safe levels of ATIII throughout the perioperative period.
Hereditary antithrombin III (ATIII) deficiency is an autosomal-dominant condition present in one in 500 to 5000 adults, predisposing them to venous thromboembolism (VTE). ATIII deficient patients require the administration of exogenous ATIII concentrate to allow effective perioperative thromboprophylaxis with heparinoid products. We describe the successful perioperative administration of ATIII concentrate and anticoagulant products that permitted the use of neuraxial anaesthesia. This case report demonstrates two successful and uncomplicated neuraxial procedures with perioperative administration of human-derived ATIII concentrate within a multidisciplinary setting. The presence of a multidisciplinary anaesthetist-run perioperative service permitted the timely and safe preparation of a patient presenting with ATIII deficiency. The patient provided informed consent to the reporting of his details.
Cases
A 47-year-old man presented for bilateral total hip arthroplasty, secondary to avascular necrosis. He had known ATIII deficiency with a history of bilateral lower limb deep vein thrombosis. ATIII levels ranged between 37% and 66% (normal 80% to 120%) in the 12 months preoperatively. His platelet count was within the normal range and his screening for factor V Leiden mutation was negative. The patient was normally maintained on warfarin with a target International Normalized Ratio (INR) of 2.0 to 3.0. His other significant history was of chronic pain with concurrent opiate use. A staged bilateral hip arthroplasty was planned. A period of six months between right and left arthroplasty was negotiated with the surgeon. Prior to the first procedure the patient was identified in the perioperative clinic as high risk, and in consultation with his haematologist a perioperative plan was developed. Informed consent for intrathecal anaesthesia and administration of ATIII concentrate was obtained.
First procedure
Warfarin was ceased four days preoperatively and therapeutic enoxaparin and ATIII concentrate (Thrombotrol®-VF; CSL Ltd, Melbourne, Victoria) commenced. Timing and doses are described in Figure 1 . Intrathecal anaesthesia was provided 26 hours post last enoxaparin dose (bupivacaine 12.5 mg, fentanyl 25 μg, morphine 100 μg) via a single pass of a 25G Sprotte needle at L4/5. The intraoperative period was unremarkable. Six hours postoperatively, the patient was recommenced on enoxaparin 40 mg bd. Warfarin was recommenced on day one, aiming for an INR >2.0, at which time enoxaparin and ATIII concentrate were ceased. There were no VTE or significant bleeding events.
Second Procedure
Warfarin was ceased four days preoperatively and therapeutic enoxaparin and ATIII commenced. Timing and doses are described in Figure 2 . On this occasion the ATIII concentrate was administered the day before the procedure instead of the day of surgery on the advice of the patient's haematologist. Intrathecal anaesthesia was provided 24 hours post last enoxaparin dose (bupivacaine 12.5 mg with fentanyl 25 μg) via a single pass of a 25G sprotte needle at L4/5. The intraoperative period was unremarkable. Postoperatively, the patient was recommenced on enoxaparin 40 mg bd and received ATIII concentrate at 2000 units every 48 hours. Warfarin was recommenced on day four (due to a surgical concern regarding wound ooze) aiming for an INR of 2.0 to 3.0. Enoxaparin was increased to 90 mg on day five due to delayed warfarinisation. There were no VTE or significant bleeding events. Delayed discharge at day 12 was due to a surgical wound complication.
Discussion
This report describes the successful use of neuraxial anaesthesia on two occasions in a patient with ATIII deficiency corrected with human-derived ATIII concentrate. The decision to offer neuraxial anaesthesia over general anaesthesia was based on his history of significant pre-procedural pain and patient preference. Intrathecal single-shot anaesthesia was thought to be the safest method on consultation with the patient's treating haematologist. It is associated with less tissue disruption when compared to epidural techniques. The risks of bleeding were thought to be low from a theoretical standpoint, although there was a scarcity of evidence in relation to neuraxial procedures. The timing of ATIII concentrate administration was varied between the two procedures with regard to the preoperative dose being 48 hours prior to the procedure in the first instance and 24 hours in the second instance. The monitoring of ATIII levels has been reported. However, in this instance of a short duration of therapy, it was thought unnecessary. For prolonged therapy, where warfarin cannot be introduced early (e.g. pregnancy, neurosurgery) monitoring of ATIII levels should be considered.
ATIII is a natural inhibitor of thrombin and other serine proteases within the coagulation cascade. Hereditary ATIII deficiency is an autosomal dominant condition present in one in 500 to 5000 adults, predisposing them to VTE. It was first described in 1965 as a familial thrombophilia and carrying a risk of VTE of 6% to 66%, depending on genotype 1,2 . There have been over 150 different mutations classified; however, it is broadly differentiated into two subtypes. Type 1 is a quantitative deficiency and Type 2 is a qualitative defect in the ATIII protein. ATIII deficiency Type 2 is further subdivided according to the defective binding site and subsequent VTE risk (Table 1) . ATIII deficiency is often described in terms of ATIII activity with the normal range of 80% to 120%. Individuals with ATIII deficiency often have levels <50% and a lifetime risk of VTE of >50%. Patients who experience a lower limb VTE have a 240% higher change of experiencing a pulmonary embolus than non-affected persons 3 . Both VTE and pulmonary embolus are more common during the perioperative period in these patients and aggressive chemical and physical prophylaxis is required.
Treatment of ATIII deficient patients is dependent on the presence or absence of prior VTE. Patients with a history of VTE have high recurrence rates estimated at 10% to 17% per year, whereas in patients without prior VTE the risk is lower at 1.7% per year 4, 5 . Given this high risk of recurrence in those that have a VTE, long-term anticoagulation is recommended with oral vitamin K antagonists targeting an INR of 2.0 to 3.0. In individuals without VTE history (often identified via screening of blood donations or familial history), there is no proven benefit of anticoagulation and the risk of bleeding contraindicates its routine use. The use of inferior vena caval filters has been described in instances where anticoagulation is contraindicated, e.g. neurosurgical procedures. ATIII replacement is recommended for patients having high-risk procedures in the perioperative or peripartum period.
The perioperative period increases the risk of VTE in the general population and the ATIII-deficient population is no exception. The challenge in the perioperative setting is to be able to cease the long-term anticoagulation and bridge the patient with a shorter-acting agent. The inherent deficiency of ATIII raises the prospect of typical agents such as low molecular weight heparin and heparin being ineffective. The availability of both human-derived and recombinant ATIII has allowed replacement of deficient or defective ATIII. ATIII therapy allows for both the intrinsic anticoagulant effect and the use of low molecular weight heparin in the perioperative period for VTE prophylaxis.
The administration of ATIII should be arranged in consultation with a haematologist, to whom these patients are often well known. Dosing of ATIII is aimed at increasing ATIII levels to an activity of 80% to 120% and then maintaining them within this range until long-term anticoagulation has been reinstituted. ATIII is available as a human-derived plasma product and as a recombinant product. Australia has access to the humanderived purified pooled plasma product, Thrombotrol-VF. The administration of 1 IU results in an increase in activity of 2.2% from baseline. The dose is derived by the following formula: Thrombotrol-VF dose IU/kg = [desired% -pre-treatment%]/2.2. The potential advantage of the recombinant product is the reduced risk of blood-borne diseases. There is also a theoretical risk of conversion of human-derived ATIII to the inactive L-isomer during viral heat treatment. There have not been any episodes of transmissible disease from ATIII replacement reported to date.
Neuraxial techniques are often favourable for both surgical factors and patient comorbid disease. The potential added benefit to ATIII patients of the reduction of VTE after neuraxial anaesthesia, as seen in the general population, is theoretical and unquantified 6 . Considerations for neuraxial techniques include the need for puncture to be delayed 24 hours post administration, the theoretical peak in ATIII levels post transfusion, and the potential implications for haematoma formation. Epidural placement for labour analgesia and subsequent caesarean section has been described in two case reports. Pamnani et al described the perioperative use of recombinant ATIII (Atryn, GTC Biotherapeutics [now rEVO Biologics], Framingham, MA, USA) and reported no complications in its use 7 . Rowbotham et al described epidural use with heparin prophylaxis, in the absence of ATIII replacement, without complication 8 . Intrathecal anaesthesia has not been described to date (with or without ATIII replacement) in the ATIII deficient population. By describing our experience it may allow others to act with more confidence in the perioperative management of ATIII deficient patients.
Conclusion
The complex and heterogeneous nature of this disease and its management in the perioperative period required close communication and cooperation between haematologist, surgeon and anaesthetist. The use of an anaesthetist-run perioperative service in our institution allowed this to occur with minimal risk to the patient and without delay to service provision. We would recommend this approach to colleagues faced with patients in similar circumstances. 
